课题基金 / 基金详情

ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -

ADULT AIDS CLINICAL TRIAL GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) -
成人艾滋病临床试验组纵向连锁随机试验 (ALLRT) -
批准号:
7606380
负责人:
MITCHELL J GOLDMAN
金额:
$28.11万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-12-01 至 2007-11-30

项目摘要

项目成果

MITCHELL J GOLDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金, 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 ALLRT方案是一系列计划中的前瞻性荟萃分析和交叉方案分析,将从HIV感染者的既定纵向和横向队列中收集数据,这些人群已被前瞻性随机纳入批准的母公司AACTG临床试验,并同意接受长期跟踪,目的是评估与有效的抗逆转录病毒疗法长期治疗相关的临床、病毒学、免疫学和药理学结果。最初进入ALLRT方案的所有受试者将同时参与一项有效的AACTG研究,或在过去8周内完成一项亲本临床试验。进入ALLRT方案的受试者可能会收集额外的血液和数据,用于临床、病毒学、免疫学和药理学评估。长期随访将继续在双亲AACTG方案的范围内进行,直到这些研究结束或达到终点。对于进入ALLRT方案的受试者,如果他们到达其父方案或其父方案的终点,否则参与替代AACTG随机试验的时间不能立即获得或不可行,则将根据ALLRT方案中概述的时间表继续进行临床、病毒学、免疫学和药理学监测的长期随访。大约2500-3000名艾滋病毒感染者、未接受抗逆转录病毒治疗的受试者以及参加过父母AACTG临床试验并同意长期接受临床、病毒学、免疫学和药理学终点追踪的受试者将被纳入研究对象。ALLRT方案不提供任何治疗。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ALLRT protocol is a planned series of prospective meta-analyses and cross-protocol analyses of data to be collected from an established longitudinal and cross-sectional cohort of HIV-infected individuals who have been prospectively randomized into approved parent AACTG clinical trials, and who have agreed to be followed long-term for the purpose of evaluating clinical, virologic, immunologic, and pharmacologic outcomes associated with long-term treatment with potent antiretroviral therapies. All subjects initially entered into the ALLRT protocol will be participating concurrently in a potent AACTG study or have completed participation in a parent clinical trial within the previous 8 weeks. Subjects entered into the ALLRT protocol may have additional blood and data collected for clinical, virologic,immunologic,and pharmacologic evaluation. Long-term follow-up will continue within the context of parent AACTG protocols until those studies close or an endpoint is reached. For subjects entered into the ALLRT protocol who reach an endpoint on their parent protocol or their parent protocol participation otherwise ends, and for whom participation in an alternative AACTG randomized trial is not immediately available or feasible, long-term follow up with clinical, virologic, immunologic, and pharmacologic monitoring will continue according to the schedule outlined in the ALLRT protocol. Approximately 2500-3000 subjects who are HIV-infected, antiretroviral treatment naive subjects and previously or currently treated subjects who are entered into parent AACTG clinical trials and who agree to be followed long-term for clinical, virologic, immunologic, and pharmacologic endpoints will be enrolled. No treatment is provided through the ALLRT protocol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IMPACT OF THERAPEUTIC DRUG MONITORING ON VIROLOGIC RESPONSE TO A SALVAGE REGIMEN
ACUTE HIV INFECTION AND EARLY DISEASE RESEARCH PROGRAM (AIEDRP)
A MULTICENTER, OPEN-LABEL, CONTROLLED PHASE II STUDY TO EVALUATE SAFETY AND I
SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG HIV-1-INFECTED
海外基金